INBX — Inhibrx Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2007919 ·
Last close
$99.61
Market Cap
$1.47B
52W High
$155.29
52W Low
$28.16
ADV30
347,507
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -32,149,000 | -36,650,000 | 154,222,000 | 133,344,000 | 207,199,000 |
| Mar 2026 | 0 | — | -30,927,000 | -33,441,000 | 183,967,000 | 161,657,000 | 205,002,000 |
| Dec 2025 | 0 | — | -30,923,000 | -32,834,000 | 146,478,000 | 124,220,000 | 138,485,000 |
| Sep 2025 | 0 | — | -33,812,000 | -35,256,000 | 177,471,000 | 153,088,000 | 140,641,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,925,000
Investing CF
$-7,000
Financing CF
$77,069,000
CapEx
$-47,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.39
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,628,000
Inventory
—
Receivables
$186,000
ST Investments
—
EBIT TTM
$-117,167,000
Pretax Income TTM
$-130,183,000
Interest Exp TTM
$13,016,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-125,604,000
Free Cash Flow
$-85,104,872
Enterprise Value
$1,656,480,768
Total Cash
$133,344,000
Total Debt
$181,626,000
Shares Out
14,717,660
Trailing EPS
$-8.88
Book Value
$-3.60
ROE
-1773.6%
ROA
-43.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,300,000 | -135,025,000 | -140,055,000 | 146,478,000 | 138,485,000 | 7,993,000 | -129,794,000 |
| Dec 2024 | 200,000 | -331,448,000 | 1,687,572,000 | 180,767,000 | 47,183,000 | 133,584,000 | -194,409,000 |
| Dec 2023 | 1,800,000 | -219,221,000 | -241,361,000 | 307,893,000 | 264,390,000 | 43,503,000 | -193,309,000 |
| Dec 2022 | 1,301,000 | -115,323,000 | -115,325,000 | 16,645,000 | 23,945,000 | -7,300,000 | -90,811,000 |
TTM Snapshot
Revenues TTM
$119,000
NetIncome TTM
$-138,964,000
OpCashFlow TTM
$0
Assets (Latest)
$146,478,000
Forward EPS
$-8.76
Max Pain — expiry 2027-01-15
max pain strike: $60.00 · spot: $98.77 · call oi: 2,981 · put oi: 324
Expected Move to 2027-01-15:
±$36.85
(37.31%) —
implied range
$61.92 –
$135.62
· ATM straddle on $100.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | $1.45B | $26.05 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.52B | $4.67 | — |
| IMCR | Immunocore Holdings plc | $1.58B | $30.72 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.62B | $34.74 | — |
| IMTX | Immatics N.V. | $1.27B | $8.37 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
2026-09-24 17:07 · Yahoo
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
2026-09-16 00:29 · Yahoo
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
2026-09-08 12:51 · Yahoo
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
2026-09-08 11:30 · Yahoo
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
2026-09-04 20:00 · Yahoo
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
2026-06-15 13:15 · Yahoo
Inhibrx Reports First Quarter 2026 Financial Results
2026-05-14 20:02 · Yahoo
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?
2026-05-12 14:12 · Yahoo
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
2026-05-11 16:08 · Yahoo
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
2026-05-11 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-09-23 16:59:17 | 2026-09-23 | Kayyem Jon Faiz | Dir | P - Purchase | 100 | 5000 | 500000 |